Peter de Bruijn

7.3k citations

138 papers · 5.8k · 2 hit papers · h-index 35

Impact in

Pollution top 0.2%
- Wastewater Treatment and Nitrogen Removal
Oncology top 1%
- Cancer Treatment and Pharmacology
- Drug Transport and Resistance Mechanisms

Papers in

Oncology 56
- Cancer Treatment and Pharmacology 23
- Drug Transport and Resistance Mechanisms 14
- Neutropenia and Cancer Infections 10
- Colorectal Cancer Treatments and Studies 8
Molecular Biology 36
- Cancer therapeutics and mechanisms 26

Co-authors: Mike S. M. Jetten (5 shared papers)Lesley A. Robertson (5 shared papers)A.A. van de Graaf (4 shared papers)J. Gijs Kuenen (3 shared papers)Alex Sparreboom (46 shared papers)Ron H.J. Mathijssen (92 shared papers)Walter J. Loos (36 shared papers)Jaap Verweij (38 shared papers)
Journals: Journal of Pharmaceutical and Biomedical Analysis (13 papers)Journal of Clinical Oncology (7 papers)Clinical Cancer Research (7 papers)Clinical Pharmacokinetics (7 papers)Cancer Chemotherapy and Pharmacology (6 papers)
Partner nations: Netherlands United States Sweden

In The Last Decade

Peter de Bruijn

135 papers receiving 5.6k citations

Peter de Bruijn's Hit Papers

align trajectories log scale

Autotrophic growth of anaerobic ammonium-oxidizing micro-organisms in a fluidized bed reactor 1996 · 1.2k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1996 Microbiology
1995 Applied and Environmental Microbiology

Peers

Countries citing papers authored by Peter de Bruijn

Since Specialization

Citations

This map shows the geographic impact of Peter de Bruijn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter de Bruijn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter de Bruijn more than expected).

Fields of papers citing papers by Peter de Bruijn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter de Bruijn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter de Bruijn. The network helps show where Peter de Bruijn may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter de Bruijn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter de Bruijn Line = papers co-authored together Peter de Bruijn links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 138 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Autotrophic growth of anaerobic ammonium-oxidizing micro-organisms in a fluidized bed reactor Microbiology ·A.A. van de Graaf, Peter de Bruijn, Lesley A. Robertson, Mike S. M. Jetten, J. Gijs Kuenen Hit paper breakdown →	1996	1243
2	Anaerobic oxidation of ammonium is a biologically mediated process Applied and Environmental Microbiology ·A.A. van de Graaf, A. Mulder, Peter de Bruijn, Mike S. M. Jetten, Lesley A. Robertson, J. Gijs Kuenen Hit paper breakdown →	1995	613
3	Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. PubMed ·Alex Sparreboom, Lia van Zuylen, Eric Brouwer, Walter J. Loos, Peter de Bruijn, Hans Gelderblom, Marrimuthoo Pillay, Kees Nooter, G. Stoter, Jaap Verweij	1999	278
4	Metabolic pathway of anaerobic ammonium oxidation on the basis of 15N studies in a fluidized bed reactor Microbiology ·A.A. van de Graaf, Peter de Bruijn, Lesley A. Robertson, Mike S. M. Jetten, J. Gijs Kuenen	1997	267
5	Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. PubMed ·Diederik F.S. Kehrer, Alex Sparreboom, Jaap Verweij, Peter de Bruijn, C A Nierop, J van de Schraaf, Elisabeth J. Ruijgrok, M J de Jonge	2001	150
6	Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles Cancer Chemotherapy and Pharmacology ·Lia van Zuylen, M. O. Karlsson, Jaap Verweij, Eric Brouwer, Peter de Bruijn, Kees Nooter, G. Stoter, Alex Sparreboom	2001	110
7	Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes JNCI Journal of the National Cancer Institute ·Ron H.J. Mathijssen, Floris A. de Jong, Ron H. N. van Schaik, Erin R. Lepper, Lena E. Friberg, T. Rietveld, Peter de Bruijn, Wilfried J. Graveland, William D. Figg, J. Verweij, Alex Sparreboom	2004	102
8	Modulation of Irinotecan Metabolism by Ketoconazole Journal of Clinical Oncology ·Diederik F.S. Kehrer, Ron H.J. Mathijssen, Jaap Verweij, Peter de Bruijn, Alex Sparreboom	2002	99
9	Irinotecan (CPT-11) metabolism and disposition in cancer patients. PubMed ·Alex Sparreboom, M J de Jonge, Peter de Bruijn, E. Brouwer, Kees Nooter, Walter J. Loos, R J van Alphen, Ron H.J. Mathijssen, G. Stoter, Jaap Verweij	1998	97
10	Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non–Small-Cell Lung Cancer Journal of Clinical Oncology ·Roelof W. F. van Leeuwen, Robert Peric, Koen G. A. M. Hussaarts, Emma Kienhuis, Nikki S. IJzerman, Peter de Bruijn, Cor van der Leest, Henk Codrington, Jeroen S. Kloover, Bronno van der Holt, Joachim G.J.V. Aerts, Teun van Gelder, Ron H.J. Mathijssen	2016	94
11	Elongated Multiple Electronic Cascade and Cyclization Spacer Systems in Activatible Anticancer Prodrugs for Enhanced Drug Release The Journal of Organic Chemistry ·Franciscus M. H. de Groot, Walter J. Loos, Ralph Koekkoek, Leon W. A. van Berkom, Guuske F. Busscher, Antoinette E. Seelen, Carsten Albrecht, Peter de Bruijn, Hans W. Scheeren	2001	92
12	CYP3A422* Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity Clinical Cancer Research ·Anne‐Joy M. de Graan, Laure Elens, Jason A. Sprowl, Alex Sparreboom, Lena E. Friberg, Bronno van der Holt, Pleun J. de Raaf, Peter de Bruijn, Frederike K. Engels, Ferry A.L.M. Eskens, Erik A.C. Wiemer, Jaap Verweij, Ron H.J. Mathijssen, Ron H. N. van Schaik	2013	91
13	Measurement of Fraction Unbound Paclitaxel in Human Plasma Drug Metabolism and Disposition ·Eric Brouwer, Jaap Verweij, Peter de Bruijn, Walter J. Loos, Marrimuthoo Pillay, Dirk Buijs, Alex Sparreboom	2000	85
14	Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein Anti-Cancer Drugs ·Alex Sparreboom, André Planting, Roxanne C. Jewell, Maria EL van der Burg, Ate van der Gaast, Peter de Bruijn, Walter J. Loos, Kees Nooter, LuWanda H Chandler, Elaine Paul, Paul Wissel, Jaap Verweij	1999	80
15	Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel Clinical Cancer Research ·Anne‐Joy M. de Graan, Cynthia S. Lancaster, Amanda Obaidat, Bruno Hagenbuch, Laure Elens, Lena E. Friberg, Peter de Bruijn, Shuiying Hu, Alice A. Gibson, Gitte Hoffmann Bruun, Thomas J. Corydon, Torben Stamm Mikkelsen, Aisha L. Walker, Guoqing Du, Walter J. Loos, Ron H. N. van Schaik, Sharyn D. Baker, Ron H.J. Mathijssen, Alex Sparreboom	2012	79
16	Determination of Doxorubicin and Doxorubicinol in Plasma of Cancer Patients by High-Performance Liquid Chromatography Analytical Biochemistry ·Peter de Bruijn, Jaap Verweij, Walter J. Loos, Herman J. Kolker, André Planting, Kees Nooter, Gerrit Stoter, Alex Sparreboom	1999	79
17	Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection Journal of Chromatography B Biomedical Sciences and Applications ·Peter de Bruijn, Jaap Verweij, Walter J. Loos, Kees Nooter, G. Stoter, Alex Sparreboom	1997	77
18	Prophylaxis of Irinotecan-Induced Diarrhea with Neomycin and Potential Role for **UGT1A128*** Genotype Screening: A Double-Blind, Randomized, Placebo-Controlled Study The Oncologist ·Floris A. de Jong, Diederik F.S. Kehrer, Ron H.J. Mathijssen, Geert‐Jan Creemers, Peter de Bruijn, Ron H. N. van Schaik, André Planting, Ate van der Gaast, Ferry A.L.M. Eskens, J Janssen, Jan B. Ruit, Jaap Verweij, Alex Sparreboom, Maja J.A. de Jonge	2006	76
19	Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces Journal of Chromatography B Biomedical Sciences and Applications ·Alex Sparreboom, Peter de Bruijn, Maja J.A. de Jonge, Walter J. Loos, Gerrit Stoter, Jaap Verweij, Kees Nooter	1998	72
20	Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection Journal of Chromatography B Biomedical Sciences and Applications ·Alex Sparreboom, Peter de Bruijn, Kees Nooter, Walter J. Loos, G. Stoter, Jaap Verweij	1998	72

About Peter de Bruijn

Peter de Bruijn is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Pharmacology and Pharmacology, having authored 138 papers that have together received 5.8k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (26 papers), Cancer Treatment and Pharmacology (23 papers), Drug Transport and Resistance Mechanisms (14 papers), Pharmacogenetics and Drug Metabolism (13 papers), Lung Cancer Treatments and Mutations (12 papers), Neutropenia and Cancer Infections (10 papers), Colorectal Cancer Treatments and Studies (8 papers) and Prostate Cancer Treatment and Research (7 papers). The work is most often cited by research in Pollution (2.0k citations), Oncology (1.6k citations), Environmental Engineering (787 citations), Industrial and Manufacturing Engineering (439 citations) and Health, Toxicology and Mutagenesis (661 citations). Peter de Bruijn has collaborated with scholars based in Netherlands, United States and Sweden. Frequent co-authors include Mike S. M. Jetten, Lesley A. Robertson, A.A. van de Graaf, J. Gijs Kuenen, Alex Sparreboom, Ron H.J. Mathijssen, Walter J. Loos, Jaap Verweij, Kees Nooter and J. Gijs Kuenen. Their work appears in journals such as Journal of Pharmaceutical and Biomedical Analysis, Journal of Clinical Oncology, Clinical Cancer Research, Clinical Pharmacokinetics and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Peter de Bruijn

Impact in

Papers in i

In The Last Decade

Peter de Bruijn

Peter de Bruijn's Hit Papers

Peers

Countries citing papers authored by Peter de Bruijn

Fields of papers citing papers by Peter de Bruijn

All Works

About Peter de Bruijn

Explore authors with similar magnitude of impact

Papers in